Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora A kinase inhibitor, in patients with advanced solid tumors.
Clinical Cancer Research.
Times cited: 80
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: Safety, pharmacokinetics, and pharmacodynamics.
Molecular Cancer Therapeutics.
Times cited: 53